Methylated-(3′′)-Epigallocatechin Gallate Analog Suppresses Tumor Growth in Huh7 Hepatoma Cells Via Inhibition of Angiogenesis

REFERENCES

• Yang C: Inhibition of carcinogenesis by tea. Nature 389, 134–135, 1997.
   PubMed Web of Science ®Google Scholar
• Moyers S and Kumar N: Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev 62, 204–211, 2004.
   PubMed Web of Science ®Google Scholar
• Adhami V, Ahmad N, and Mukhtar H: Molecular targets for green tea in prostate cancer prevention. J Nutr 133, 2417S–2424S, 2003.
   PubMed Web of Science ®Google Scholar
• Lu G, Xiao H, You H, Lin Y, Jin H, et al.: Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin. Clin Cancer Res 14, 4981–4988, 2008.
   PubMed Web of Science ®Google Scholar
• Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, et al.: Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett 245, 232–241, 2007.
   PubMed Web of Science ®Google Scholar
• Ju J, Hong J, Zhou J, Pan Z, Bose M, et al.: Inhibition of intestinal tumorigenesis in Apcmin/ +mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res 65, 10623–10631, 2005.
   PubMed Web of Science ®Google Scholar
• Qin J, Xie L, Zheng X, Wang Y, Bai Y, et al.: A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. Biochem Biophys Res Commun 354, 852–857, 2007.
   PubMed Web of Science ®Google Scholar
• Khan N and Mukhtar H: Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett 269, 269–280, 2008.
   PubMed Web of Science ®Google Scholar
• Yang CS and Wang H: Mechanistic issues concerning cancer prevention by tea catechins. Mol Nutr Food Res 55, 819–831, 2011.
   PubMed Web of Science ®Google Scholar
• Kerbel R and Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2, 727–739, 2002.
   PubMed Web of Science ®Google Scholar
• Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2, 795–803, 2002.
   PubMed Web of Science ®Google Scholar
• Yang CS and Wang X.: Green tea and cancer prevention. Nutr Cancer 62, 931–937, 2010.
   PubMed Web of Science ®Google Scholar
• Pang X, Yi Z, Zhang J, Lu B, Sung B, et al.: Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 70, 1951–1959, 2010.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhu QY, Tsang D, and Huang Y: Degradation of green tea catechins in tea drinks. J Agric Food Chem 49, 477–482, 2001.
   PubMed Web of Science ®Google Scholar
• Landis-Piwowar KR, Wan SB, Wiegand RA, Kuhn DJ, Chan TH, et al.: Methylation suppresses the proteasome-inhibitory function of green tea polyphenols. J Cell Physiol 213, 252–260, 2007.
   PubMed Web of Science ®Google Scholar
• Kawase M, Wang R, Shiomi T, Saijo R, and Yagi K.: Antioxidative activity of (-)-epigallocatechin-3-(3′′-O-methyl)gallate isolated from fresh tea leaf and preliminary results on its biological activity. Biosci Biotechnol Biochem 64, 2218–2220, 2000.
   PubMed Web of Science ®Google Scholar
• Yang C, Maliakal P, and Meng X: Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 42, 25–54, 2002.
   PubMed Web of Science ®Google Scholar
• Wen W, Lu J, Zhang K, and Chen S.: Grape seed extract inhibits angiogenesis via suppression of the vascular endothelial growth factor receptor signaling pathway. Cancer Prev Res (Phila) 1, 554–561, 2008.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Ueno H, and Shibuya M.: VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 2221–2230, 1999.
   PubMed Web of Science ®Google Scholar
• Yang C, Wang X, Lu G, and Picinich S.: Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 9, 429–439, 2009.
   PubMed Web of Science ®Google Scholar
• Shirakami Y, Shimizu M, Adachi S, Sakai H, Nakagawa T, et al.: (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci 100, 1957–1962, 2009.
   PubMed Web of Science ®Google Scholar
• Lee M, Maliakal P, Chen L, Meng X, Bondoc F, et al.: Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 11, 1025–1032, 2002.
   PubMed Web of Science ®Google Scholar
• Chen L, Lee M, Li H, and Yang C.: Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab Dispos 25, 1045–1050, 1997..
   PubMed Web of Science ®Google Scholar
• Chow H, Cai Y, Alberts D, Hakim I, Dorr R, et al.: Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 10, 53–58, 2001.
   PubMed Web of Science ®Google Scholar
• Lambert J, Lee M, Lu H, Meng X, Hong J, et al.: Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr 133, 4172–4177, 2003.
   PubMed Web of Science ®Google Scholar
• Xu H, Becker CM, Lui WT, Chu CY, Davis TN, et al.: Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo. Fertil Steril 96, 1021–1028, 2011.
   PubMed Web of Science ®Google Scholar
• Fassina G, Venè R, Morini M, Minghelli S, Benelli R, et al.: Mechanisms of i nhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res 10, 4865–4873, 2004.
   PubMed Web of Science ®Google Scholar
• Zhu BH, Zhan WH, Li ZR, Wang Z, He YL, et al.: (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J Gastroenterol 13, 1162–1169, 2007.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Shirakami Y, Sakai H, Yasuda Y, et al.: (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells. Chem Biol Interac 185, 247–252, 2010.
   PubMed Web of Science ®Google Scholar
• Kondo T, Ohta T, Igura K, Hara Y, and Kaji K: Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding. Cancer Lett 180, 139–144, 2002.
   PubMed Web of Science ®Google Scholar
• Rodriguez SK, Guo W, Liu L, Band MA, Paulson EK, et al.: Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int J Cancer 118, 1635–1644, 2006.
   PubMed Web of Science ®Google Scholar
• Meng X, Lee M, Li C, Sheng S, Zhu N, et al.: Formation and identification of 4’-O-methyl-(-)-epigallocatechin in humans. Drug Metab Dispos 29, 789–793, 2001.
   PubMed Web of Science ®Google Scholar
• Nanjo F, Goto K, Seto R, Suzuki M, Sakai M, et al.: Scavenging effects of tea catechins and their derivatives on 1,1-diphenyl-2-picrylhydrazyl radical. Free Radic Biol Med 21, 895–902, 1996.
   PubMed Web of Science ®Google Scholar
• Yang H, Sun DK, Chen D, Cui QC, Gu YY, et al.: Antitumor activity of novel fluoro-substituted (-)-epigallocatechin-3-gallate analogs. Cancer Lett 292, 48–53, 2010.
   PubMed Web of Science ®Google Scholar
• Landis-Piwowar K, Huo C, Chen D, Milacic V, Shi G, et al.: A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res 67, 4303–4310, 2007.
   PubMed Web of Science ®Google Scholar
• Lambert JD, Sang S, Hong J, Kwon SJ, et al.: Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. Drug Metab Dispos 34, 2111–2116, 2006.
   PubMed Web of Science ®Google Scholar
• Yasue M, Ikeda M, Nagai H, Sato K, Mitsuda H, et al.: The clinical effecs and the safety of the intakes of ‘benifuuki’ green tea in patients with perennial allergic rhinitis. J Japan Society Clin Nutrition 27, 33–51, 2005.
   Google Scholar